Intralesional interferon‐alpha therapy in advanced malignant melanoma

Cancer

Volumn 61, Issue 6, 1988, Pages 1071-1074

  Wussow, Peter Von ^a   Block, Berthold ^a   Hartmann, F ^a   Deicher, Helmuth ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON;

CONTROLLED STUDY; FEMALE; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMAN; INTERFERON TYPE I; MALE; MELANOMA; MIDDLE AGE; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 0023870584     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19880315)61:6<1071::AID-CNCR2820610603>3.0.CO;2-T     Document Type: Article

References (14)

1. DTIC‐therapy in metastatic malignant melanoma: A simplified dose schedule
2. Sequential combination chemotherapy for disseminated melanoma: SWOG study
3. Effects of cloned human leukocytes interferons in the human tumor stem cell assay
4. Interferon as an inhibitor of cell growth: Studies with mouse melanoma cells
5. Inhibition of growth of B16 murine malignant melanoma by exogenous IFN
6. Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase II Trial
7. Phase II study of low‐dose recombinant leukocyte A interferon in disseminated melignant melanoma
8. Phase II study of recombinant leukocyte A interferon (rIFN A) in disseminated malignant melanoma
9. Comparison of intramuscular and intravenous recombinant alpha‐2 interferon in melanoma and other cancer
10. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma
11. Effective use of recombinant human alpha‐2 interferon (IFN‐α2) in metastatic melignant melanoma (MMM): A comparison of two regimens
12. A microassay for mouse and human interferon
13. Recombinant leukocyte A interferon: Pharmakokinetics, single‐dose tolerance and biologic effects in cancer patients